Novocure provides patients with an innovative cancer treatment based on alternating electric fields through the use of wearable, portable, FDA-approved treatments for glioblastoma (GBM) called Optune®, and for Malignant Pleural Mesothelioma (MPM) called Optune Lua®. Patients are also using this device in a multitude of undergoing clinical trials for other solid tumor cancers.

*Please Note: The Optune or Optune Lua* device may be on an individual's head or torso.

To treat aggressive brain cancer, the Optune medical device works by creating Tumor Treating Fields (TTFields). TTFields are electric fields that help slow down or stop cancer cell division and may destroy some cancer cells completely.

With Optune, TTFields therapy is delivered right into the area of the body where the cancer is located, using four adhesive patches called transducer arrays.

**Remember:**

- Listen to the traveler and acknowledge any documentation provided and engage in an interactive dialog with the traveler to determine the best screening options available.
- Do not require or convince travelers with disabilities or medical conditions to use screening technology.
- Do not ignore the traveler’s request for medical supplies/equipment to be opted-out of technology, such as x-ray screening.
- Engage in a dialogue to best understand the traveler’s needs and inform them of their screening options. This promotes a calm checkpoint and limits distractions.

*Optune® was approved by the FDA under the Premarket Approval (PMA) pathway. Optune Lua® was approved under the Humanitarian Device (HDE) pathway*